Baird Medical Investment Holdings Ltd. announced the launch of the first treatment of a benign thyroid tumour using ablation technology in the important Central California region of the San Joaquin Valley. This launch is committed to helping more people to get access to advanced medical care. This helps to show the strength of the company and its growing presence across the U.S. region.
The first inaugural procedure was performed by Tim Beck, a respected endocrine surgeon at Dignity Health Medical Group. Under his leadership, the medical team uses specialised technology to perform a precise and minimally invasive treatment. The system is highly efficient and capable of implementing technology value in the high-volume hospital setting.
This launch shows clear pathway for a business plan with advanced tools and the company helping more doctors to use interventional treatment, which improves patient care and support, indirectly hitting the company's goal.
Baird Medical is a next-generation device that focuses on minimally invasive diagnosis and treatment. The company dedicatedly develop surgical robotic systems and advance minimal minimally invasive surgical tools to improve precision and patient outcomes.
The main purpose is to improve patient care through technology and advanced diagnostic solutions. Beyond surgical support, the main aims to create intelligent systems that help guide diagnosis and support preventive healthcare.
Baird Medical is FDA 510(k) and its products are used in more than 30 leading hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. This company is also the market leader in China for thyroid microwave devices and related products. In addition, minimally invasive treatment products are expanding into more than 20 countries worldwide.
This statement includes plans and expectations, risks and uncertainties, which may differ from the actual result. The given statement is based on current estimation and assumption which may probably change. We must not rely on forward looking statement as new risks may come up or not that we cannot predict.
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
